AR114596A1 - Composición farmacéutica y método de fabricación - Google Patents

Composición farmacéutica y método de fabricación

Info

Publication number
AR114596A1
AR114596A1 ARP190100727A ARP190100727A AR114596A1 AR 114596 A1 AR114596 A1 AR 114596A1 AR P190100727 A ARP190100727 A AR P190100727A AR P190100727 A ARP190100727 A AR P190100727A AR 114596 A1 AR114596 A1 AR 114596A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
composition according
range
hydroxypropyl cellulose
sodium
Prior art date
Application number
ARP190100727A
Other languages
English (en)
Inventor
Yong Yang
Original Assignee
Komipharm Int Australia Pty Ltd
Panaphix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900954A external-priority patent/AU2018900954A0/en
Application filed by Komipharm Int Australia Pty Ltd, Panaphix Inc filed Critical Komipharm Int Australia Pty Ltd
Publication of AR114596A1 publication Critical patent/AR114596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud se refiere a las composiciones farmacéuticas que comprenden una sal del ácido arsenioso y a los métodos de fabricación de las composiciones farmacéuticas. Reivindicación 1: Una composición farmacéutica adecuada para la administración oral que comprende: a) un núcleo sólido compuesto por metaarsenito de sodio o metaarsenito de potasio y los siguientes excipientes de uso farmacéutico aceptable: i) un material de relleno o diluyente en un rango de aproximadamente 5 a 95% p/p, ii) un desintegrante en un rango de 10 y 90% p/p, iii) un deslizante en un rango de aproximadamente 0,1 a 5% p/p, iv) un lubricante en un rango de aproximadamente 0,1 a 5% p/p, y v) opcionalmente, un aglutinante en un rango de 0 a aproximadamente 30% p/p; y b) un cubierta entérica que comprende un polímero entérico; donde los excipientes de uso farmacéutico aceptable están seleccionados de tal forma que la oxidación de metaarsenito a metaarseniato está minimizada, donde el porcentaje en peso de la cubierta entérica es de aproximadamente 6% p/p a aproximadamente 20% p/p con respecto al peso total de la composición farmacéutica, y donde el grosor de la cubierta es de aproximadamente 6,5% a aproximadamente 15% del grosor de la composición farmacéutica. Reivindicación 5: La composición farmacéutica según cualquiera de las reivindicaciones 1 a 4, en la que el material de relleno o diluyente se selecciona a partir de fosfato de calcio dibásico anhidro, almidón parcialmente pregelatinizado, celulosa microcristalina silicificada, celulosa microcristalina, sulfato de calcio dihidratado, lactosa, fosfato hidrógeno de calcio, carbonato de calcio, carbonato de sodio, fosfato de calcio, fosfato de sodio o una mezcla de los mismos. Reivindicación 8: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 7, en la que el desintegrante se selecciona a partir de L-hidroxipropilcelulosa, almidón parcialmente pregelatinizado, crospovidona, almidón de papa, almidón de maíz, almidón glicolato de sodio y ácido algínico. Reivindicación 15: La composición farmacéutica según la reivindicación 14, en la que el lubricante es estearil fumarato de sodio. Reivindicación 17: La composición farmacéutica según la reivindicación 16, en la que el aglutinante es L-hidroxipropil celulosa (hidroxipropilcelulosa poco sustituida), una mezcla de L-hidroxipropil celulosa (hidroxipropilcelulosa poco sustituida) e hidroxipropil celulosa, o almidón parcialmente pregelatinizado. Reivindicación 20: La composición farmacéutica según la reivindicación 19, en la que el polímero de cubierta entérica es un copolímero de ácido metacrílico y acrilato de etilo (1:1). Reivindicación 30: Un método según la reivindicación 28, en el que el paso (a) comprende tres pasos: i) mezclar el API con una parte del material de relleno para formar una premezcla de API; ii) mezclar el deslizante, el desintegrante y, opcionalmente, el aglutinante con la premezcla de API; y luego iii) agregar el lubricante (que opcionalmente se ha mezclado con una parte de la mezcla desde el paso (ii)) y, a continuación, mezclarlo. Reivindicación 32: Un método para el tratamiento de una enfermedad o afección en un sujeto, que comprende la administración oral al sujeto de una composición farmacéutica según cualquiera de las reivindicaciones 1 a 26, donde la enfermedad o afección se selecciona a partir de una neoplasia maligna sólida, metástasis ósea o enfermedad neoplásica metastásica, tumor pulmonar primario o metastásico, cánceres urogenitales, leucemia, dolor, cánceres de la sangre, cánceres metastásicos, dolor por cáncer, dolor crónico, inflamación, trastornos autoinmunitarios, trastornos inmunológicos, retinopatía diabética, vasculopatía diabética, neuralgia diabética, síntomas asociados con insulitis y colitis ulcerosa.
ARP190100727A 2018-03-22 2019-03-21 Composición farmacéutica y método de fabricación AR114596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2018900954A AU2018900954A0 (en) 2018-03-22 Pharmaceutical composition and method of manufacture

Publications (1)

Publication Number Publication Date
AR114596A1 true AR114596A1 (es) 2020-09-23

Family

ID=67988234

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100727A AR114596A1 (es) 2018-03-22 2019-03-21 Composición farmacéutica y método de fabricación

Country Status (20)

Country Link
US (1) US20210000746A1 (es)
EP (1) EP3768247A4 (es)
JP (1) JP7419333B2 (es)
KR (1) KR20210016513A (es)
CN (1) CN112135608A (es)
AR (1) AR114596A1 (es)
AU (1) AU2019239671A1 (es)
BR (1) BR112020019425A2 (es)
CA (1) CA3094115A1 (es)
CL (1) CL2020002407A1 (es)
CO (1) CO2020012963A2 (es)
EA (1) EA202092186A1 (es)
IL (1) IL277456A (es)
JO (1) JOP20200238A1 (es)
MA (1) MA52088A (es)
MX (1) MX2020009756A (es)
PE (1) PE20211479A1 (es)
PH (1) PH12020551518A1 (es)
SG (1) SG11202009174WA (es)
WO (1) WO2019178643A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230123135A1 (en) * 2020-02-16 2023-04-20 Komipharm International Australia Pty Ltd Method of treatment using meta-arsenite

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5318973A (en) * 1993-06-07 1994-06-07 Vyzkumny Ustav Pro Farmacii A Biochemii Neuroprotective composition for preventing or treating of central nervous system impairment
JP4036936B2 (ja) * 1997-10-22 2008-01-23 古河機械金属株式会社 排酸の処理法
US6262086B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
CA2471715A1 (en) * 2001-12-28 2003-07-17 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof
US20090061022A1 (en) * 2004-10-08 2009-03-05 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
KR20090058423A (ko) * 2007-12-04 2009-06-09 심형섭 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20120045520A1 (en) * 2008-08-21 2012-02-23 Sang Bong Lee Pharmaceutical composition comprising arsenite for the treatment of malignancy
MX2012002922A (es) * 2009-09-18 2012-09-07 Kominox Inc Metodos para tratar tumores del cerebro.

Also Published As

Publication number Publication date
JP2021518434A (ja) 2021-08-02
AU2019239671A1 (en) 2020-10-01
JP7419333B2 (ja) 2024-01-22
CO2020012963A2 (es) 2020-10-30
EA202092186A1 (ru) 2020-12-16
JOP20200238A1 (ar) 2020-09-20
IL277456A (en) 2020-11-30
CL2020002407A1 (es) 2021-04-09
PE20211479A1 (es) 2021-08-05
CN112135608A (zh) 2020-12-25
SG11202009174WA (en) 2020-10-29
EP3768247A1 (en) 2021-01-27
CA3094115A1 (en) 2019-09-26
PH12020551518A1 (en) 2021-07-12
MX2020009756A (es) 2021-01-29
WO2019178643A1 (en) 2019-09-26
KR20210016513A (ko) 2021-02-16
BR112020019425A2 (pt) 2020-12-29
US20210000746A1 (en) 2021-01-07
EP3768247A4 (en) 2021-12-29
MA52088A (fr) 2021-01-27

Similar Documents

Publication Publication Date Title
US9173938B2 (en) Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders
MX2022008456A (es) Inhibidores de mek y usos terapeuticos de estos.
RU2020129238A (ru) Фармацевтические композиции для лечения муковисцидоза
Shiraiwa et al. JAK/STAT3 and NF-κB signaling pathways regulate cancer stem-cell properties in anaplastic thyroid cancer cells
AR114596A1 (es) Composición farmacéutica y método de fabricación
US8409614B2 (en) Low dosage forms of risedronate or its salts
ES2802252T3 (es) Formulación de comprimido oral que consiste en la combinación fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares
RU2013131004A (ru) Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek
JP2007518815A5 (es)
EP3423061A1 (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
US20130183353A1 (en) Low dosage forms of risedronate or its salts
JP2019523258A (ja) エソメプラゾール、又は薬学的に許容可能なその塩を含むｐＨ依存性薬物放出特性が改善した剤形
JP2016502981A5 (es)
JP6321314B2 (ja) 光安定性を向上したシロドシン含有着色錠剤
JP2004510761A (ja) 増殖性疾病を治療するための置換（ｅ）−スチリルベンジルスルホン
JP2017002022A (ja) ボリコナゾール含有製剤
JP2016013980A (ja) テルミサルタン含有フィルムコーティング錠剤
WO2014157443A1 (ja) イリノテカン塩酸塩水和物を含有する抗腫瘍剤
MX2021013222A (es) Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
JP2017014151A (ja) 光安定性を向上した、シロドシンを含有する有核錠
WO2020197101A3 (ko) 이중 약물 방출을 위한 약물 전달체
PL422125A1 (pl) Rozpuszczalne w wodzie, inteligentne kompleksy złota (III), sposób wytwarzania rozpuszczalnych w wodzie, inteligentnych kompleksów złota (III) i ich zastosowanie
TR201619828A2 (en) MULTI LAYERED TABLET COMPOSITIONS OF DABIGATRAN
WO2020171757A1 (en) Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
TR2022007542A2 (tr) Li̇nagli̇pti̇n i̇çeren fi̇lm kapli tablet